Active ingredient
- rifaximin
Legal Category
POM: Prescription only medicine
POM: Prescription only medicine
The Patient Information Leaflet (PIL) is the leaflet included in the pack with a medicine. It is written for patients and gives information about taking or using a medicine. It is possible that the leaflet in your medicine pack may differ from this version because it may have been updated since your medicine was packaged.
Below is a text only representation of the Patient Information Leaflet. The original leaflet can be viewed using the link above.
The text only version may be available in large print, Braille or audio CD. For further information call emc accessibility on 0800 198 5000. The product code(s) for this leaflet is: PL20011/0020.
TARGAXAN 550 mg film-coated tablets
Package Leaflet: Information for the user
TARGAXAN® 550 mg film-coated tablets
rifaximin
Read all of this leaflet carefully before you start taking this medicine because it contains important information for you.
What is in this leaflet:
1. What Targaxan is and what it is used for
2. What you need to know before you take Targaxan
3. How to take Targaxan
4. Possible side effects
5. How to store Targaxan
6. Contents of the pack and other information
1. What TARGAXAN is and what it is used for
Targaxan contains the active substance rifaximin. Targaxan is an antibiotic that destroys bacteria, which can cause a disease called hepatic encephalopathy (symptoms include agitation, confusion, muscle problems, difficulty in speaking and in some cases coma).
Targaxan is used in adults with liver disease to reduce the recurrence of episodes of overt hepatic encephalopathy.
Targaxan can either be used alone or more commonly together with medicines containing lactulose (a laxative).
2. What you need to know before you take TARGAXAN
Do not take Targaxan:
Warnings and precautions
Talk to your doctor or pharmacist before taking Targaxan.
While you are taking Targaxan your urine may turn a reddish colour. This is quite normal.
Treatment with any antibiotic including rifaximin may cause severe diarrhoea. This can happen several months after you have finished taking the medicine. If you have severe diarrhoea during or after using Targaxan you should stop taking Targaxan and contact your doctor immediately.
If your liver problems are severe your doctor will need to observe you carefully.
Targaxan contains sodium
This medicine contains less than 1 mmol sodium (23 mg) per tablet, that is to say essentially ‘sodium-free’.
Children and adolescents
Targaxan is not recommended for children and adolescents aged under 18 years. This medicine has not been studied in children and adolescents.
Other medicines and Targaxan
Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines.
Please tell your doctor if you are taking any of the following medicines:
Pregnancy and breast-feeding
If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking any medicine.
It is not known if Targaxan can harm your unborn baby. Targaxan is therefore not to be used if you are pregnant.
It is not known if rifaximin may be passed to your baby in breast milk. Targaxan is therefore not to be used if you are breast-feeding.
Driving and using machines
Targaxan does not normally affect the ability to drive and use machines, but may cause dizziness in some patients. If you feel dizzy you should not drive or operate machinery.
3. How to take TARGAXAN
Always take this medicine exactly as your doctor has told you. Check with your doctor or pharmacist if you are not sure.
The recommended dose is 1 tablet twice a day taken with a glass of water.
Continue taking Targaxan until your doctor tells you to stop.
If you take more Targaxan than you should
If you take more than the recommended number of tablets, even if you do not notice any problems, please contact your doctor.
If you forget to take Targaxan
Take the next dose at its normal time. Do not take a double dose to make up for a forgotten tablet.
If you stop taking Targaxan
Do not stop taking Targaxan without talking to your doctor first because your symptoms may return.
If you have any further questions on the use of this medicine, ask your doctor or pharmacist.
4. Possible side effects
Like all medicines, this medicine can cause side effects, although not everybody gets them.
Stop taking Targaxan and tell your doctor IMMEDIATELY if you have any of the following side effects:
Uncommon (may affect up to 1 in 100 people):
Not known (frequency cannot be estimated from the available data):
Other side effects that may occur
Common (may affect up to 1 in 10 people):
Uncommon (may affect up to 1 in 100 people):
Rare (may affect up to 1 in 1,000 people):
Not known (frequency cannot be estimated from the available data):
Reporting of side effects:
If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via Yellow Card Scheme Website: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.
By reporting side effects you can help provide more information on the safety of this medicine.
5. How to store TARGAXAN
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiry date which is stated on the carton and the blister after EXP. The expiry date refers to the last day of that month.
Targaxan does not require any special storage conditions.
Do not throw away any medicine via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help to protect the environment.
6. Contents of the pack and other information
What Targaxan contains
The active substance is rifaximin. Each tablet contains 550 mg rifaximin.
The other ingredients are:
What Targaxan looks like and contents of the pack
Pink oval curved film-coated tablets marked with “RX” on one side.
Targaxan is available in cartons of 14, 28, 42, 56 and 98 tablets.
Not all pack-sizes may be marketed.
Marketing Authorisation Holder:
Manufacturer:
Or
This leaflet was last revised in 03/2021
This medicinal product is authorised in the Member States of the EEA under the following names:
TARGAXAN®: Belgium, Finland, Ireland, Luxembourg, United Kingdom
XIFAXAN®: Denmark, Germany, Netherlands, Norway, Sweden.
Other sources of information
If you need the information on this leaflet in an alternative format, such as large print, or Braille please ring 0800 198 5000.
Norgine House, Widewater Place, Moorhall Road, Harefield, Middlesex, UB9 6NS
+44 (0)1895 826 600